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Tischbirek et al. (2012) in this issue of Neuron reveal that weak base antipsychotic drugs inhibit presynaptic
function in an activity-dependent manner via their release from synaptic vesicles.The treatment of schizophrenia has relied
heavily on antipsychotic drugs (APDs)
that primarily impact on the dopami-
nergic system, principally at D2 receptors
(Strange, 2001). APDs act with high
affinity (in the low nanomolar range) with
clinical efficacy closely matching their
published potency at D2 receptors
(Strange, 2001). However, some aspects
of APDaction are difficult to explain based
solely on their action at D2 receptors. For
example, the therapeutic benefit of APDs
increases slowly during treatment, an
occurrence which correlates with their
accumulation in tissue (Agid et al., 2003).
APDs also inhibit voltage-gated sodium
(Ogata and Narahashi, 1989) and calcium
channels (Sah and Bean, 1994), impli-
cating them in the control of neuro-
transmitter release. However, the clinical
relevance of this potential presynaptic
mechanism of action was largely dis-
missed, since it requires micromolar con-
centrations of APDs.
It has been known for years that APDs
such as clozapine and haloperidol exhibit
increased accumulation in brain (Strange,
2001). This phenomenon has been as-
cribed to the fact that many APDs are
weak bases, allowing them to accumulate
in acidic intracellular compartments such
as endosomes or synaptic vesicles (SVs)
(Rayport and Sulzer, 1995). This en-
richment suggests that accumulation of
weak-base APDs in SVs could create a
highly concentrated reservoir of drug for
release during synaptic activity. In this
issue of Neuron, Tischbirek et al. (2012)
reveal that APDs are released during SV
fusion at concentrations sufficient to
inhibit presynaptic voltage-gated sodium
channels. This results in reduced presyn-
aptic calcium influx, which limits sub-
sequent SV exocytosis and neurotrans-mitter release (Figure 1). Therefore, in
addition to established high affinity
effects on dopaminergic receptors by
the free circulating drug, Tischbirek et al.
(2012) describe a novel lower-affinity,
use-dependent effect at voltage-gated
sodium channels that only manifests
during evoked neurotransmitter release.
To demonstrate vesicular accumulation
of APDs, the fluorescent reporter lyso-
tracker red (LTR) was used as a mimic of
drug behavior. LTR is also a weak base,
and was shown to accumulate in SVs
by either colocalization with presyn-
aptic markers or photoconversion fol-
lowed by ultrastructural analysis (Tisch-
birek et al., 2012). Importantly Tischbirek
and colleagues also demonstrated that
LTR was released on stimulation with a
train of action potentials, indicating that
the dye (and by extension APDs) could
be released by SV exocytosis.
Parallel mathematical modeling studies
predicted that APDs would be accumu-
lated inside SVs in the micromolar range.
Therefore, Tischbirek et al. (2012) next
questioned whether acute application
of such concentrations of APDs modu-
lated presynaptic function. The effects
of four APDs were assessed (haloper-
idol, chlorpromazine, clozapine, and ris-
peridone). SV exocytosis was monitored
using the pH-sensitive fluorescent gen-
etic reporter synaptopHluorin (Sankara-
narayanan and Ryan, 2000) and calcium
influx measured using the fluorescent
dye fluo-4. In all cases, acute application
of APDs inhibited both calcium influx and
SV exocytosis evoked by action potential
stimulation in a dose-dependent manner.
Both effects were due to an upstream
inhibition of voltage-gated sodium chan-
nels, since acute APD application had
no effect on SV exocytosis elicited byNeuroKCl, a stimulus that bypasses these
channels.
This observed inhibition of presynaptic
function by APDs can only be physiologi-
cally relevant if the drugs were (1) concen-
trated inside SVs and (2) released on
neuronal stimulation. To test this, Tisch-
birek et al. (2012) applied APDs to
cultured neurons which had previously
accumulated LTR. This resulted in dis-
placement of LTR, providing indirect
evidence that APDs were accumulating
in SVs. Unfortunately, APD enrichment
inside SVs was not directly confirmed
(by using fluorescent-labeled APDs for
example; Rayport and Sulzer, 1995).
Therefore, a direct estimate of the intrave-
sicular concentration of APDs could not
be determined. Importantly, however,
APDs were shown to be released on
neuronal stimulation in vivo, in experi-
ments performed using animals treated
with clinically relevant doses of haloper-
idol. In these experiments, a challenge
with a depolarizing pulse raised extracel-
lular levels of haloperidol in parallel with
classical neurotransmitters such as dopa-
mine. This result was consistent with
APDs being accumulated inside SVs and
then released in response to stimulation.
The most important aspect of the work
was the demonstration of the functional
consequences of vesicular delivery of
APDs on neurotransmitter release. Tisch-
birek et al. (2012) showed that cultured
neurons previously treated with APDs
displayed a form of presynaptic autoin-
hibition. Key experiments revealed that
during relatively mild stimulation, neurons
previously exposed to APDs displayed
a small reduction in the extent of SV
exocytosis. However, this inhibition was
much larger when cultures were chal-
lenged with higher stimulation intensities.n 74, June 7, 2012 ª2012 Elsevier Inc. 765
Figure 1. Vesicular Accumulation and Release of Antipsychotic
Drugs Inhibits Presynaptic Function
Circulating nanomolar concentrations of weak base antipsychotic drugs
(APDs) are sufficient to exert effects at high affinity sites (D2 receptors) but
insufficient to impact on other lower affinity targets (sodium channels) in
resting neurons. APDs accumulate in SVs at micromolar concentrations.
Upon SV exocytosis (activity), APDs are released into the synaptic cleft, where
they can exert an autoinhibitory action on presynaptic function by inhibiting
sodium channels and thus downstream calcium influx and neurotransmitter
release.
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observed in intact slices,
where glutamatergic neuro-
transmission in the hippo-
campus was inhibited in a
use-dependent manner. Intri-
guingly these use-dependent
effects were accentuated in
the nucleus accumbens,
which has a high concentra-
tion of dopaminergic innerva-
tion, suggesting a region-,
or potentially circuit-specific
bias of inhibition. In this con-
text, it will be critical for
future studies to determine
whether the vesicular delivery
of APDs disproportionately
impacts on key circuits and
receptor systems implicated
in schizophrenia (Lisman
et al., 2008).
The results described
above suggested that neuro-transmitter release was being inhibited
by APDs that were released during
SV fusion. This was confirmed in ele-
gant experiments where the vesicular
pH gradient was collapsed using the
V-ATPase inhibitor folimycin in neuronal
culture. Inhibition of the V-ATPase re-
moved the driving force for APD accumu-
lation into SVs, and thus depleted the
vesicular reservoir of drug. Folimycin
treatment resulted in a partial reversal of
the APD-dependent inhibition of both SV
exocytosis and calcium influx, confirming
the vesicular nature of APD release.
By integrating single-cell fluorescence
imaging approaches and in vitro and
in vivo physiology, Tischbirek et al.
(2012) have revealed a novel delivery
mechanism for APDs that may contribute
to their medicinal action. Unsurprisingly
this work highlights areas for future study.
The first is the observed lack of effect on
the SV pH gradient by APD accumulation.
Most weak bases that accumulate into
acidic compartments become protonated
and thus either collapse or reduce the pH
gradient (Cousin and Nicholls, 1997).
However, this does not occur with weak
base APDs, even at predicted micromolar
concentrations. This is an important point,
since an increase in pH will reduce neuro-
transmitter uptake into SVs. A potential
explanation for this observed absence of
effect is that vesicular pH was monitored766 Neuron 74, June 7, 2012 ª2012 Elsevierusing the genetic reporter synapto-
pHluorin. A significant percentage of syn-
aptopHluorin is expressed at the plasma
membrane in culture (Sankaranarayanan
and Ryan, 2000) (where it is fluorescent)
meaning the potential dynamic range for
monitoring increases in SV pH (and fluo-
rescence) will be small. In support,
collapse of the vesicular pH gradient
using folimycin only increased synapto-
pHluorin fluorescence by 50% (Tischbirek
et al., 2012). Similarly, the displacement of
LTR by APDs was taken as evidence of
drug accumulation in SVs. However it is
unclear why LTR would be displaced if
the pH gradient is unaffected. One future
test to confirm that APDs have no effect
on neurotransmitter uptake into SVs
would be to utilize recently developed
fluorescent false neurotransmitters (Gu-
bernator et al., 2009) to determine any
modulation of their uptake and release
by these drugs during KCl-evoked SV
turnover.
The central hypothesis of the work out-
lined by Tischbirek et al. (2012) is that
APDs are released during SV fusion to
inhibit presynaptic sodium channels.
However, do APDs remain in the synaptic
cleft at micromolar concentrations for
a sufficient time to exert their effect?
Glutamate is stored in SVs at high milli-
molar levels. Extensive modeling studies
have revealed that released glutamateInc.only remains at such con-
centrations within 100 nm of
the release site and even
then dissipates to micromolar
levels within less than 100
microseconds, a dilution of
approximately 100-fold (Dia-
mond and Jahr, 1997; Ragha-
vachari and Lisman, 2004). If
these parameters were reca-
pitulated for APDs, it would
confound their proposed
mechanism of action, since
drug would be diluted below
its IC50 for channel antago-
nism. However, glutamate is
a charged, hydrophilic mole-
cule whose synaptic concen-
tration is controlled by both
diffusion and reuptake by
transport proteins, whereas
APDs are lipophilic molecules
with no known transport tar-
gets. These factors may re-tard the exit of APDs from the tight,
membrane-delimited synaptic cleft. Im-
portantly, Tischbirek et al. (2012) also
demonstrated that sodium channels are
inhibited by APDswith far greater potency
(two orders of magnitude) when they are
in their inactivated state, suggesting they
may exert a biological effect even after
their dilution in the cleft. It will therefore
be critical for future studies to determine
the APD concentration in the synapse,
while considering the clinically relevant
circulating free concentration of drug.
Finally this study reiterates the extraor-
dinary fact that SVs recycle perfectly well
with an altered luminal cargo or indeed no
cargo at all (Cousin and Nicholls, 1997).
The demonstration by Tischbirek et al.
(2012) that key psychoactive drugs are
accumulated inside SVs and delivered
with high precision provides a potentially
useful strategy for designing compounds
with an activity-dependent mode of
action. By altering the pKa of lead
compounds, novel drugs could be de-
signed that are accumulated inside SVs.
Vesicular accumulation would have no
obvious effects on presynaptic function
per se but could be potentially highly
effective in targeting therapies to a range
of mental health disorders and neurode-
generative conditions where synaptic
dysfunction is a critical early step in
disease progression (Bear et al., 2004;
Neuron
PreviewsArendt, 2009; Milnerwood and Raymond,
2010).
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The Mg2+ block of NMDA-type glutamate receptors (NMDARs) is crucial to their function as synaptic coinci-
dence detectors. An analysis ofDrosophila expressing aMg2+-independent NMDARbyMiyashita et al. (2012)
in this issue of Neuron concludes that the Mg2+ block is required primarily for long-term memory.Donald Hebb first proposed that syn-
apses between two neurons would be
strengthened if they showed coincident
activity. This idea was hugely influential
because such ‘‘Hebbian’’ plasticity could
theoretically explain how memories
formed, particularly associations be-
tween temporally linked events. Subse-
quently, Bliss and Lomo (1973) discov-
ered long-term potentiation (LTP), a
phenomenon in which synaptic strength
is enhanced following bursts of synaptic
activity. Thus, LTP gained particular noto-
riety as one of the underlying mecha-
nisms of learning and memory and
considerable effort was focused on un-
raveling mechanisms of coincidence
detection and the subsequent synaptic
plasticity. From these studies, NMDA-
type glutamate receptors (NMDARs)
emerged as a class of ionotropic recep-
tors whose pharmacological or geneticperturbations disrupted both LTP and
learning and memory (Traynelis et al.,
2010). NMDARs are now understood as
pivotal molecules required for coinci-
dence detection, synaptic plasticity, and
learning and memory in the central
nervous system (CNS).
A voltage-dependent Mg2+ block of
NMDARs allows them to function as
Hebbian coincidence detectors (Mayer
et al., 1984; Nowak et al., 1984). Binding
by glutamate alone is insufficient for
channel activation as Mg2+ remains
bound to a site in the channel pore,
effectively blocking ion transport. Eviction
of this Mg2+ ion additionally requires
membrane depolarization. Thus, the
coincidence of presynaptic glutamate
release and strong depolarizing potential
in the postsynaptic neuron is required
for the opening of NMDAR channels.
Subsequent Ca2+ influx through theopen channel serves as a trigger for
synaptic plasticity.
Mouse models with mutations specific
to the NMDA Mg2+ block site result in
developmental defects and/or defects
in complex behavior, suggesting that
coincidence detection is required for
normal NMDAR function in vivo (Single
et al., 2000; Rudhard et al., 2003).
However, for two reasons, neither these
studies nor the observations of abnormal
LTP and learning in these mutant mice
(Chen et al., 2009) directly address the
role of coincidence detection in vivo. First,
all known Mg2+ block mutations in murine
NMDARs also decrease Ca2+ conduc-
tance. Thus, it is unclear whether the
resultant phenotypes are due to Mg2+
block-specific effects or reduced calcium
permeability. Second, because Mg2+
block mutants show severe develop-
mental defects and early lethality, it isn 74, June 7, 2012 ª2012 Elsevier Inc. 767
